CollabRx and OncoDNA Partner in Molecular Diagnostics

CollabRx and OncoDNA Partner in Molecular Diagnostics

SAN FRANCISCO, April 4, 2013 (GLOBE NEWSWIRE) -- CollabRx, Inc. (Nasdaq:CLRX),
a data analytics company focused on informing clinical decision making in
molecular medicine, and OncoDNA, SA, a Belgium company that provides DNA next
generation sequencing (NGS) tests for clinical use in cancer, today announced
a multi-year agreement to purchase CollabRx SaaS-based technology and content
resources to be used in conjunction with OncoDNA's cancer mutation panels.

OncoDNA and CollabRx will develop a combined test and medical informatics
solution by pairing the results of cancer mutational panels developed by
OncoDNA with clinically actionable and dynamically updated knowledge provided
by CollabRx.Such knowledge includes the clinical impact of specific
mutational profiles and associated therapeutic strategies such as drugs and
clinical trials and is supported by CollabRx's large and growing network of
over 75 leading clinical practitioners in the U.S. and Europe.

"NGS-based tests are increasingly becoming a routine part of clinical care for
cancer patients, but the complexity of the genetic data from tumor mutations
is outpacing the ability of physicians to stay current with advanced
treatments," said Jean-Pol Detiffe, Founder & CEO of OncoDNA."We are excited
to partner with CollabRx to close this knowledge gap and enable physicians who
order OncoDNA tests to access highly credible knowledge provided by CollabRx
to aid in the interpretation of test results."

The partnership, CollabRx's first outside the United States, will leverage the
company's semantic integration platform, a proprietary technology that enables
CollabRx scientists and physicians to dynamically update the company's
molecular oncology knowledge base with the latest medical and scientific data
available in the public domain.

"Our agreement with OncoDNA reflects our commitment to partner with
best-in-class laboratories and diagnostic companies and is a significant step
forward in our strategy to serve high-growth markets outside of the U.S.,"
said Thomas Mika, Chairman, President & CEO of CollabRx. "We are excited to
work with OncoDNA to establish a leadership position in the clinical next
generation sequencing market in Europe by providing ordering physicians with
clinically relevant interpretation of test results as a seamless part of the
reporting process."

The OncoDNA partnership demonstrates CollabRx's accelerating pace of business,
product and channel development in 2013.This new milestone attests to the
growing adoption of CollabRx technology and interpretive analytics in top-tier
laboratories worldwide as a standard aspect of test reporting for clinical
cancer sequencing.

About CollabRx

CollabRx, Inc. (Nasdaq:CLRX) is a recognized leader in cloud-based expert
systems to inform healthcare decision-making. CollabRx uses information
technology to aggregate and contextualize the world's knowledge on
genomics-based medicine with specific insights from the nation's top cancer
experts, starting with the area of greatest need: advanced cancers in patients
who have effectively exhausted the standard of care. More information may be
obtained at http://www.collabrx.com.

About OncoDNA

Through its founders, OncoDNA has over 60 years' expertise in medical
diagnostics and was founded by a team of experts with many years' experience
in DNA sequencing and diagnostic analyses in oncology.More information can be
obtained at http://www.oncodna.com.

CollabRx Safe Harbor Statement

This press release includes forward-looking statements about CollabRx's
anticipated results that involve risks and uncertainties. Some of the
information contained in this press release, including, but not limited to,
statements as to industry trends and CollabRx's plans, objectives,
expectations and strategy for its business, contains forward-looking
statements that are subject to risks and uncertainties that could cause actual
results or events to differ materially from those expressed or implied by such
forward-looking statements. Any statements that are not statements of
historical fact are forward-looking statements. When used, the words
"believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and
the like, and/or future tense or conditional constructions ("will," "may,"
"could," "should," etc.), or similar expressions, identify certain of these
forward-looking statements. Important factors which could cause actual results
to differ materially from those in the forward-looking statements are detailed
in filings made by CollabRx with the Securities and Exchange Commission.
CollabRx undertakes no obligation to update or revise any such forward-looking
statements to reflect subsequent events or circumstances.

CONTACT: CollabRx Contacts:
         Thomas R. Mika, CEO
         CollabRx, Inc.
         415-248-5350
        
         Robert Ferri Partners, LLC
         Robert Ferri
         (415) 575-1589 (direct)
         robert.ferri@robertferri.com
        
         OncoDNA Contacts
         Jean-Pol Detiffe, CEO
         OncoDNA SA
         +3271347899
         jp.detiffe@oncodna.com

CollabRx, Inc. Logo
 
Press spacebar to pause and continue. Press esc to stop.